ODM 103

Drug Profile

ODM 103

Alternative Names: ODM-103

Latest Information Update: 10 Feb 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Orion
  • Class Antiparkinsonians
  • Mechanism of Action Catechol-O-methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 04 Feb 2015 Discontinued - Phase-I for Parkinson's disease (In volunteers) in Germany (PO)
  • 01 Sep 2014 Orion Corporation completes a phase I trial in Parkinson's disease (In volunteers) in Germany (NCT01688089)
  • 01 Nov 2013 Orion suspends enrolment in a phase I trial in healthy volunteers in Germany (NCT01688089)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top